More quality of life for cancer patients through therapy with medical cannabis

June 29, 2022
iStock-1178459721-1200x800.jpg

Many people who suffer from cancer have distressing symptoms such as pain and fatigue, but also  psychological complaints such as insomnia, depression or anxiety. An Israeli research team has now presented a promising prospective study with oncological patients.  The long-term study provides evidence for a reduction in the overall burden of cancer after therapy with medical cannabis. 

 

Structure of the cancer study 

The research group surveyed oncology patients over a total period of 2.5 years at various points in time with regard to individual pain perception, quality of sleep, sexual activity, depression and anxiety. At the beginning of the study, a total of 324 patients were involved, and the last survey was conducted with 126 individuals. The average age in the study group was 64 years, and women slightly outnumbered men, accounting for 59 percent. All participants suffered from advanced stage cancer (“Stage IV”). Breast, colon, lung and ovarian tumors were most prevalent. Therapy was with well-tolerated cannabis oils, the dosage of which was documented separately.    

Results 

The therapy with medicinal cannabis brought a significant improvement in almost all questioned aspects. The authors described the reduction in the overall burden of cancer symptoms after 6 months as particularly striking: The median decreased by 18 percent compared with baseline. Side effects were observed, but were not severe and remained stable during therapy.   

Reduction of pain symptoms, less analgesics needed 

Another interesting finding: treatment with medicinal cannabis led to a reduction in pain symptoms and less need for opiates, but also other painkillers such as non-steroidal analgesics as well as anticonvulsants or antidepressants.   

Significant improvements after 6 months of therapy 

Last but not least, the results of the study seem to indicate that the success of treatment with medical cannabis depends, among other things, on the duration of therapy. Therefore, the statistically significant changes in symptoms appeared only after 6 months of continuous intake of cannabinoids. In a previous study, the authors investigated the short-term effects of pharmaceutical cannabis therapy and found no significant improvements in cancer symptoms.  

source  

Aviram, Joshua, et al. “The Effectiveness and Safety of Medical Cannabis for Treating Cancer Related Symptoms in Oncology Patients.” Frontiers in Pain Research, vol. 3, 20 May2022, 10.3389/fpain.2022.861037. Accessed 24 June 2022. 

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

HEADQUARTERS

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg, Germany

REPRESENTATIVE OFFICES

Berlin
Rosenthaler Str. 34
10178 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain